CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a human vaccine against Leishmaniasis, a disease affecting millions globally. By mimicking natural infection processes and enhancing immune response, the vaccine seeks to provide effective protection against this neglected tropical disease.
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated.
Leishmaniasis caused by Leishmania spp is one of them and poses a grave health risk to an estimated 350 million people across the world.
Among the three clinical patterns of Leishmaniasis (cu…
ETNA BIOTECH SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Roma
Type: Research institute
Activity type: Research Organisations
SME: No
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC
Portugal, Porto
Type: Research institute
Activity type: Research Organisations
SME: No
Spain, Madrid
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
